[go: up one dir, main page]

DK2282764T3 - Leverspecifikke nukleinsyreregulerende elementer samt fremgangsmåder og anvendelser heraf - Google Patents

Leverspecifikke nukleinsyreregulerende elementer samt fremgangsmåder og anvendelser heraf

Info

Publication number
DK2282764T3
DK2282764T3 DK09735371.8T DK09735371T DK2282764T3 DK 2282764 T3 DK2282764 T3 DK 2282764T3 DK 09735371 T DK09735371 T DK 09735371T DK 2282764 T3 DK2282764 T3 DK 2282764T3
Authority
DK
Denmark
Prior art keywords
applications
methods
nucleic acid
regulatory elements
specific nucleic
Prior art date
Application number
DK09735371.8T
Other languages
English (en)
Inventor
Marinee Chuah
Thierry Vandendriessche
Bleser Pieter De
Original Assignee
Vib Vzw
Life Sciences Res Partners Vzw
Univ Gent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40790549&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2282764(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vib Vzw, Life Sciences Res Partners Vzw, Univ Gent filed Critical Vib Vzw
Application granted granted Critical
Publication of DK2282764T3 publication Critical patent/DK2282764T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK09735371.8T 2008-04-22 2009-04-21 Leverspecifikke nukleinsyreregulerende elementer samt fremgangsmåder og anvendelser heraf DK2282764T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12518108P 2008-04-22 2008-04-22
PCT/EP2009/054724 WO2009130208A1 (en) 2008-04-22 2009-04-21 Liver-specific nucleic acid regulatory elements and methods and use thereof

Publications (1)

Publication Number Publication Date
DK2282764T3 true DK2282764T3 (da) 2019-10-14

Family

ID=40790549

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09735371.8T DK2282764T3 (da) 2008-04-22 2009-04-21 Leverspecifikke nukleinsyreregulerende elementer samt fremgangsmåder og anvendelser heraf

Country Status (8)

Country Link
US (5) US9617548B2 (da)
EP (3) EP2282764B2 (da)
JP (5) JP5797551B2 (da)
AU (1) AU2009240054B2 (da)
CA (1) CA2722238C (da)
DK (1) DK2282764T3 (da)
ES (1) ES2746907T5 (da)
WO (1) WO2009130208A1 (da)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009130208A1 (en) 2008-04-22 2009-10-29 Vib Vzw Liver-specific nucleic acid regulatory elements and methods and use thereof
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
CA2778945A1 (en) 2009-10-29 2011-05-05 Vib Vzw Cardiac-specific nucleic acid regulatory elements and methods and use thereof
US9102949B2 (en) 2010-04-23 2015-08-11 University Of Massachusetts CNS targeting AAV vectors and methods of use thereof
WO2011133874A1 (en) 2010-04-23 2011-10-27 University Of Massachusetts Multicistronic expression constructs
EP2561075B1 (en) 2010-04-23 2018-06-27 University of Massachusetts Aav-based treatment of cholesterol-related disorders
US20110312001A1 (en) 2010-06-15 2011-12-22 Emile Nuwaysir Compendium of ready-built stem cell models for interrogation of biological response
EP3318634A1 (en) 2011-04-21 2018-05-09 University of Massachusetts Raav-based compositions and methods for treating diseases involving dominant-negative or gain of function mutations
EP3513802B1 (en) 2012-10-26 2023-11-29 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof
WO2014063753A1 (en) 2012-10-26 2014-05-01 Vrije Universiteit Brussel Hyper-active factor ix vectors for liver-directed gene therapy of hemophilia 'b' and methods and use thereof
DK2911687T3 (da) 2012-10-26 2019-05-13 Univ Brussel Vrije Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf
CA2901747A1 (en) 2013-02-22 2014-08-28 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
CA2931848A1 (en) 2013-12-09 2015-06-18 Sangamo Biosciences, Inc. Methods and compositions for genome engineering
PL3097197T3 (pl) * 2014-01-21 2021-06-28 Vrije Universiteit Brussel Mięśniowo-specyficzne elementy regulatorowe kwasów nukleinowych oraz sposoby i ich zastosowanie
CA2939950C (en) 2014-03-09 2023-08-22 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency
US20170107486A1 (en) 2014-04-21 2017-04-20 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
WO2016044096A1 (en) * 2014-09-16 2016-03-24 Albert Einstein College Of Medicine Of Yeshiva University Repopulation of organs and tissues using a yap-ert2 fusion protein
CA2964272A1 (en) 2014-10-21 2016-04-28 Guangping Gao Recombinant aav variants and uses thereof
EP3270944B1 (en) 2015-03-17 2019-10-23 Vrije Universiteit Brussel Optimized liver-specific expression systems for fviii and fix
IL256517B2 (en) 2015-06-23 2024-06-01 Childrens Hospital Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
CN107849131A (zh) 2015-07-06 2018-03-27 瑞泽恩制药公司 多特异性抗原结合分子及其用途
AU2016343887B2 (en) 2015-10-28 2023-04-06 Sangamo Therapeutics, Inc. Liver-specific constructs, factor VIII expression cassettes and methods of use thereof
US10189888B2 (en) 2015-11-13 2019-01-29 Baxalta Incorporated Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
PE20250736A1 (es) 2016-04-15 2025-03-10 Univ Pennsylvania Terapia genica para tratar la hemofilia a
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
GB201608046D0 (en) * 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders
CN109661800B (zh) * 2016-07-11 2021-09-10 诺基亚通信公司 用于将侦听相关信息与呼叫内容相关的方法和设备
EP3509645A4 (en) 2016-09-07 2020-06-17 Sangamo Therapeutics, Inc. MODULATION OF LIVER GENES
WO2018071831A1 (en) 2016-10-13 2018-04-19 University Of Massachusetts Aav capsid designs
ES2981519T3 (es) 2016-11-04 2024-10-09 Takeda Pharmaceuticals Co Formulaciones de virus adeno-asociados
WO2018162748A1 (en) 2017-03-10 2018-09-13 Genethon Treatment of glycogen storage disease iii
AU2018241847A1 (en) 2017-03-27 2019-10-17 Vrije Universiteit Brussel Diaphragm-specific nucleic acid regulatory elements and methods and use thereof
BR112019023323A2 (pt) 2017-05-08 2020-07-21 Flagship Pioneering Innovations V, Inc. composições para facilitar a fusão de membrana e usos das mesmas
AR112057A1 (es) 2017-05-22 2019-09-18 Baxalta Inc Vectores virales que codifican variantes de fix recombinantes con mayor expresión para la terapia génica de hemofilia b
KR20240010098A (ko) * 2017-05-31 2024-01-23 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 최적화된 인간 응고 인자 ix 유전자 발현 카세트 및 이의 사용
EP3635009A1 (en) * 2017-06-07 2020-04-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
PE20212076A1 (es) 2018-02-01 2021-10-26 Homology Medicines Inc Composiciones de virus adeno-asociado para restaurar la funcion del gen pah y metodos de uso de las mismas
JP7467356B2 (ja) 2018-02-07 2024-04-15 ジェネトン ハイブリッド調節要素
IL322464A (en) 2018-02-07 2025-09-01 Regeneron Pharma Methods and compositions for administering therapeutic protein
US11306329B2 (en) 2018-02-19 2022-04-19 City Of Hope Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
EP3820509A1 (en) * 2018-07-09 2021-05-19 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
CA3106590A1 (en) 2018-07-16 2020-01-23 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
AU2019314513A1 (en) 2018-08-03 2021-01-28 Sangamo Therapeutics, Inc. Improved clinical parameters by expression of factor viii
JP7548899B2 (ja) 2018-08-08 2024-09-10 ジェネトン 糖原病ｉｉｉの処置のためのミニｇｄｅ
WO2020084162A1 (en) 2018-10-26 2020-04-30 Vrije Universiteit Brussel Liver-specific nucleic acid regulatory elements and methods and use thereof
EP3870215A1 (en) 2018-10-26 2021-09-01 Vrije Universiteit Brussel New tools for improving gene therapy and use thereof
US12496274B2 (en) 2018-11-14 2025-12-16 Flagship Pioneering Innovations V, Inc. Compositions and methods for compartment-specific cargo delivery
GB201818816D0 (en) * 2018-11-19 2019-01-02 Synpromics Ltd Regulatory nucleic acid sequences
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
GB201900741D0 (en) 2019-01-18 2019-03-06 Synpromics Ltd Liver-specifc inducible prometers and methods of use thereof
US11596671B2 (en) 2019-02-01 2023-03-07 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with increased expression
EP3956354A1 (en) 2019-04-19 2022-02-23 Genethon Gene therapy of fibroblast growth factor 23 related hypophosphatemic diseases
JP7659550B2 (ja) 2019-10-23 2025-04-09 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド アデノ随伴ウイルスベクターに基づく遺伝性血管浮腫のための遺伝子治療
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
WO2021165350A1 (en) 2020-02-18 2021-08-26 Vrije Universiteit Brussel Novel combination of nucleic acid regulatory elements and methods and uses thereof
WO2021195591A2 (en) * 2020-03-27 2021-09-30 Allen Institute Artificial expression constructs for selectively modulating gene expression in non-neuronal brain cells
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
WO2022043280A1 (en) 2020-08-24 2022-03-03 Genethon C-terminal truncated gde for the treatment of glycogen storage disease iii
CA3216353A1 (en) 2021-04-08 2022-10-13 Sana Biotechnology, Inc. Cd8-specific antibody constructs and compositions thereof
KR20240012370A (ko) 2021-04-20 2024-01-29 안자리움 바이오사이언시스 아게 아밀로-알파-1, 6-글루코시다제, 4-알파-글루카노트랜스퍼라제를 인코딩하는 dna 분자의 조성물, 이를 제조하는 방법 및 이를 사용하는 방법
CN115251653B (zh) * 2021-04-30 2023-10-27 厦门新技术集成有限公司 弹簧包、弹簧垫、家具和制作弹簧包的方法
CN117716020A (zh) 2021-05-07 2024-03-15 安斯泰来再生医药协会 产生成熟肝细胞的方法
AR126660A1 (es) 2021-07-28 2023-11-01 Univ Brussel Vrije Mejorando la eficacia de la terapia génica dirigida a músculos
CN117897492A (zh) 2021-08-04 2024-04-16 吉尼松公司 用于肌肉和cns中的基因表达的杂合启动子
US20250381294A1 (en) 2022-01-14 2025-12-18 Anjarium Biosciences Ag Compositions of DNA Molecules Encoding Factor VIII, Methods of Making Thereof, and Methods of Use Thereof
CN114891829B (zh) * 2022-05-24 2023-09-26 新乡医学院 一种肝特异性游离型表达载体和基因治疗载体及其应用
CA3252764A1 (en) 2022-06-09 2023-12-14 Institut National de la Santé et de la Recherche Médicale GDE truncated at the N-terminal level for the treatment of type III glycogen storage disease
WO2024079249A1 (en) 2022-10-12 2024-04-18 Genethon Hybrid aav vector enhancing transgene expression in the liver
WO2024188913A1 (en) 2023-03-10 2024-09-19 Genethon Induction of immune tolerance by aav vector comprising the combination of a liver detargeted capsid and a tandem liver-muscle specific promoter
WO2025003477A1 (en) 2023-06-29 2025-01-02 Genethon N-terminal truncated glycogen debranching enzymes for the treatment of glycogen storage disease iii
WO2025226943A1 (en) 2024-04-25 2025-10-30 Masonic Medical Research Laboratory Polynucleotide for hepatocyte expression of vestigial like protein 4 and method of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721096A (en) * 1991-01-24 1998-02-24 Children's Medical Center Corporation Methods of screening for compounds with ability to alter apolipoprotein AI gene expression
JPH09500534A (ja) * 1993-07-22 1997-01-21 メルク エンド カンパニー インコーポレーテッド トランスジェニック動物でのヒトインターロイキン―１βの発現
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
FR2736931B1 (fr) * 1995-07-17 1997-09-19 Univ Paris Curie Sequences regulatrices issues du gene cd4 et a expression specifique dans les lymphocytes t matures
AU735763B2 (en) * 1997-12-05 2001-07-12 Immune Response Corporation, The Novel vectors and genes exhibiting increased expression
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) * 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US20030204075A9 (en) * 1999-08-09 2003-10-30 The Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
ATE360082T1 (de) * 1999-11-16 2007-05-15 Genzyme Corp Vektoren und transgene mit regulatorischen elementen zur genverabreichung in leber
US7351813B2 (en) 2000-06-20 2008-04-01 The Board Of Trustees Of The Leland Stanford Junior University Liver-specific gene expression cassettes, and methods of use
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
EP1395293B1 (en) * 2001-05-14 2009-07-22 Gbp Ip, Llc Lentiviral vectors encoding clotting factors for gene therapy
US20030215858A1 (en) * 2002-04-08 2003-11-20 Baylor College Of Medicine Enhanced gene expression system
US20070054278A1 (en) * 2003-11-18 2007-03-08 Applera Corporation Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof
CA3050151C (en) * 2003-11-26 2023-03-07 Celera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
ES2381796T3 (es) 2004-09-22 2012-05-31 St. Jude Children's Research Hospital Expresión mejorada de Factor IX en vectores de terapia génica
TWI294461B (en) * 2004-12-28 2008-03-11 Ind Tech Res Inst Cell culture and method for screening for a compound useful in the treatment or prevention of hepatic cirrhosis
US8008468B2 (en) * 2005-02-16 2011-08-30 Benitec, Inc. RNAi expression constructs with liver-specific enhancer/promoter
EP1928504B1 (en) * 2005-08-19 2013-04-24 University of Technology, Sydney Liver-directed gene therapy
US8129510B2 (en) * 2006-03-30 2012-03-06 The Board Of Trustees Of The Leland Stanford Junior University Minigene expression cassette
US7651840B2 (en) * 2006-07-14 2010-01-26 Celera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
KR101235560B1 (ko) 2008-02-14 2013-02-25 재단법인 목암생명공학연구소 유전자 치료용 코딩 서열의 발현에 적합한 발현 벡터
EP2276855B1 (en) * 2008-03-13 2016-05-11 Celera Corporation Genetic polymorphisms associated wiith venous thrombosis, methods of detection and uses thereof
WO2009130208A1 (en) 2008-04-22 2009-10-29 Vib Vzw Liver-specific nucleic acid regulatory elements and methods and use thereof

Also Published As

Publication number Publication date
JP6963641B2 (ja) 2021-11-10
US10149914B2 (en) 2018-12-11
US12409236B2 (en) 2025-09-09
EP3586868A2 (en) 2020-01-01
CA2722238A1 (en) 2009-10-29
JP2018078898A (ja) 2018-05-24
JP6718859B2 (ja) 2020-07-08
US20230293728A1 (en) 2023-09-21
AU2009240054A1 (en) 2009-10-29
EP2282764A1 (en) 2011-02-16
JP2011517955A (ja) 2011-06-23
ES2746907T3 (es) 2020-03-09
JP2020078316A (ja) 2020-05-28
US20190046663A1 (en) 2019-02-14
US20110184049A1 (en) 2011-07-28
US20200038522A1 (en) 2020-02-06
US20170209600A1 (en) 2017-07-27
JP6272279B2 (ja) 2018-01-31
EP3586868B1 (en) 2023-11-08
CA2722238C (en) 2017-11-28
US11654201B2 (en) 2023-05-23
AU2009240054B2 (en) 2013-08-01
EP4154903A1 (en) 2023-03-29
JP5797551B2 (ja) 2015-10-21
JP2022017320A (ja) 2022-01-25
US9617548B2 (en) 2017-04-11
JP7248760B2 (ja) 2023-03-29
US10471157B2 (en) 2019-11-12
EP2282764B1 (en) 2019-07-24
ES2746907T5 (es) 2024-12-11
EP3586868A3 (en) 2020-02-26
EP2282764B2 (en) 2024-06-12
WO2009130208A1 (en) 2009-10-29
JP2016027802A (ja) 2016-02-25

Similar Documents

Publication Publication Date Title
DK2282764T3 (da) Leverspecifikke nukleinsyreregulerende elementer samt fremgangsmåder og anvendelser heraf
DK3590949T3 (da) Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf
BRPI0915142A2 (pt) polipeptídeos, ácido nucleico e usos dos mesmos
DK2049671T3 (da) Regulatoriske nukleinsyreelementer
DK2129797T3 (da) Nukleinsyrepåvisning
DK2544719T3 (da) Cd37-bindingsmolekyler og immunkonjugater deraf
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
BRPI0914558A2 (pt) dispositivo e métodos de manuseio tunular
DK2190991T3 (da) SDF-1-Bindende nucleinsyrer og anvendelsen deraf
FI20085334A0 (fi) Harjoitusmenetelmä ja -järjestelmä
GB0701253D0 (en) Nucleic acid amplification and testing
DK2913344T3 (da) Specifikke bindingsproteiner og anvendelser deraf
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
BRPI0910925A2 (pt) conjuntos de transferência de líquido e métodos relacionados
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
EP2349500A4 (en) DEVICE AND EXERCISE SYSTEM
PL2358756T3 (pl) Ludzkie przeciwciała o wysokim powinowactwie wobec pcsk9
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
BR112013013699A2 (pt) fixação de barra de exercícios e método
EP2599856A4 (en) NUCLEIC ACID AMPLIFIER AND NUCLEIC ACID TEST EQUIPMENT THEREWITH
DK2240203T3 (da) Alfa5-beta1-antistoffer og deres anvendelser
BRPI0822296A2 (pt) Transponder e livreto
DK2631291T3 (da) Nukleinsyremolekyler, der inducerer rna-interferens, og anvendelser deraf
DK1984502T3 (da) Nukleinsyre
EP2437052A4 (en) BIOSENSOR AND USE THEREOF